Gene
PDGFRB
PDGFRB is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (1), Assay-provider ledger (19), Trial mentions (176), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention PDGFRB. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 13 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 5 of 8,875 | 0.06% | not measured | |
| 2024 | 6 of 8,597 | 0.07% | not measured | |
| 2023 | 11 of 8,275 | 0.13% | 52 of 11,460 | 0.45% |
| 2022 | 9 of 8,285 | 0.11% | 52 of 13,598 | 0.38% |
| 2021 | 4 of 8,692 | 0.05% | 62 of 15,045 | 0.41% |
| 2020 | 3 of 7,640 | 0.04% | 70 of 14,459 | 0.48% |
| 2019 | 7 of 7,300 | 0.10% | 53 of 12,159 | 0.44% |
| 2018 | 2 of 6,927 | 0.03% | 50 of 11,854 | 0.42% |
| 2017 | 6 of 6,558 | 0.09% | 66 of 11,595 | 0.57% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (1)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| PDGFRB FISH Assay | PDGFRB | ARUP Laboratories, Inc. | Myelodysplastic Syndrome/Myeloproliferative Disease | 2015-12-18 |
Assay-provider ledger (19)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| BT LAB, Zhejiang, China | Reagent supplier | Clinical validation | 1 | July 17, 2025 |
| Hangzhou Eastbiopharm Co., Ltd. | Reagent supplier | Clinical validation | 1 | December 01, 2020 |
| Meso Scale Discovery | Reagent supplier | Clinical validationAnalytical validation | 1 | June 01, 2020 |
| ThermoFisher Scientific | Reagent supplier | Clinical validation | 1 | May 01, 2019 |
| Illumina | Unclassified | Analytical validation | 1 | March 25, 2019 |
Showing 5 of 19 assay-provider companies.
Trial mentions (176)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT00504153 | Trial eligibility (AACT) |
| NCT06194695 | Trial eligibility (AACT) |
| NCT00314873 | Trial eligibility (AACT) |
| NCT02109016 | Trial eligibility (AACT) |
| NCT00436605 | Trial eligibility (AACT) |
Showing 5 of 176 trial mentions.
Target-disease associations (1,089)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 14q24.1q24.3 microdeletion syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 15q11.2 microdeletion syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 16p13.11 microduplication syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| 22q11.2 microduplication syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 1,089 associations.
Vendor sourcing (544)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant reported as a pathogenic variant (ClinVar ID: VCV000973199) but it has only been observed as a somatic variant for a different phenotype, infanti... | View ClinVar record SCV002058431.1 |
| AB Science (France) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | include: * Histologically proven, metastatic or locally advanced non resectable, or recurrent post-surgery GIST * Naïve patient or patient previously treate... | View trial NCT00812240 |
| AB Science (France) | Trial sponsor | Mentioned in trial textTrial free-text mention | PDGFR | View trial NCT00812240 |
| ARIAD Pharmaceuticals (United States) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Male or female participants \>=18 years old. 2. GIST with failure of prior TKI therapy defined as: 1. Histologically confirmed metastatic and/or un... | View trial NCT01874665 |
| ARIAD Pharmaceuticals (United States) | Trial sponsor | Mentioned in trial textTrial free-text mention | PDGFR | View trial NCT01874665 |
Showing 5 of 544 sourcing records.
Trial-cited literature (814)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Reciprocal regulation of hMENA and TGF-β signaling in cancer-associated fibroblasts promotes EMT, immunosuppression, poor prognosis, and ICT resistance in NSCLC. | Journal for immunotherapy of cancer | 2026 | 1 |
| Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum-based treatment: A phase 1/2 trial. | Cancer | 2025 | 2 |
| Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial. | Signal transduction and targeted therapy | 2025 | 1 |
| Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study). | Trials | 2025 | 1 |
| Targeting pancreatic cancer metabolic dependencies through glutamine antagonism. | Nature cancer | 2024 | 116 |
Showing 5 of 814 papers.
Protein variant mentions (23)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A513T | 1 | 2018 | PMID 30220708 |
| p.A537D | 1 | 2015 | PMID 25741868 |
| p.E1081K | 1 | 2015 | PMID 25741868 |
| p.E460K | 1 | 2015 | PMID 25741868 |
| p.E485K | 1 | 2015 | PMID 25741868 |
Showing 5 of 23 variants.
Literature-extracted relations (148)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| THALIDOMIDE | Chemical | positive_correlate |
A phase 2 study of thalidomide for the treatment of radiation-induced blood-brain barrier injury. | 2023 |
| Imatinib | Chemical | associate |
World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. | 2022 |
| Nicotinamide Mononucleotide | Chemical | positive_correlate |
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. | 2021 |
| Sorafenib | Chemical | negative_correlate |
Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment. | 2020 |
| DOXORUBICIN | Chemical | associate |
First-Line Therapy for Metastatic Soft Tissue Sarcoma. | 2019 |
Showing 5 of 148 relation assertions.
Organizations publishing (584)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 39 | 2004 to 2023 |
| Dana-Farber Cancer Institute | Other | 38 | 2001 to 2024 |
| The University of Texas System | Academic | 36 | 2008 to 2023 |
| Mayo Clinic | Hospital | 32 | 2009 to 2024 |
| Harvard Medical School | Academic | 28 | 2001 to 2024 |
Showing 5 of 584 organizations.
Where PDGFRB appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- respiratory or thoracic disease
- urinary system disease
900 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects, actionable biomarkers, and human sample screening reference.